ESC Professional Premium Access

Coronary artery disease - Revascularisation 2

Event: ESC Congress 2022
Topic: Revascularisation
Session type: Moderated ePosters
Date: 27 August 2022
Time: 09:15 - 10:00

Congress Session

7 presentations in this session

Changes in cardiovascular risk factors in patients undergoing first time coronary revascularization from 2003-2020, A nationwide population study

Speaker: Miss M. Pham (Copenhagen, DK)

Percutaneous coronary intervention in elderly patients with chronic kidney disease and non-ST segment elevation acute coronary syndrome - is it worth it?

Speaker: Doctor A. Pinto Gomes (Almada, PT)

At the outer edge of STEMI time: even after 12 hours, the clock keeps ticking.

Speaker: Doctor M. Martinho (Almada, PT)

Sex, age, and cohabitation status: is it associated with perceived need of follow-up after percutaneous coronary intervention?

Speaker: Doctor N. Hjertvikrem (Bergen, NO)

Long-term clinical outcome in patients with isolated chronic total occlusion treated percutaneously or pharmacologically

Speaker: Doctor K. Frynas (Lodz, PL)

Suboptimal coronary flow after PCI in STEMI patients: clinical implications and predictors

Speaker: Doctor M. Barradas (Ponta Delgada, PT)

Results of percutaneous treatment of the left main coronary artery in elderly patients.

Speaker: Mr I. Gallo Fernandez (Cordoba, ES)

7 speakers from this session

Miss Maria Pham

Herlev and Gentofte Hospital, Copenhagen (Denmark)
0 follower

Doctor Alexandra Briosa Neves Pinto Gomes

Hospital Garcia de Orta, Almada (Portugal)
0 follower

Doctor Mariana Martinho

Hospital Garcia de Orta, Almada (Portugal)
1 presentation
0 follower

Doctor Nina Hjertvikrem

Haukeland University Hospital, Bergen (Norway)
0 follower

Doctor Karolina Frynas

Bieganski Hospital, Lodz (Poland)
0 follower

Doctor Maria Ines Barradas

Hospital Divino Espirito Santo, Ponta Delgada (Portugal)
0 follower

Mr Ignacio Gallo Fernandez

University Hospital Queen Sofia, Cordoba (Spain)
0 follower

This platform is supported by

logo Novo Nordisk